SOCRA CCRP CERTIFICATION
ACTUAL EXAM 2026/2027 | ICH GCP
E6(R3) & FDA Regulations |
Comprehensive Practice Test | Verified
Q&A | Pass Guaranteed - A+ Graded
DOMAIN 1: REGULATORY ENVIRONMENT AND
COMPLIANCE (45 Questions)
Q1: According to ICH GCP E6(R3), which principle explicitly states that the "rights, safety, and
well-being of participants prevail over the interests of science and society"?
A. Principle of Scientific Integrity
B. Principle of Risk-Based Quality Management
C. Principle of Participant Protection [CORRECT]
D. Principle of Data Governance
Correct Answer: C
Rationale: ICH E6(R3) establishes eight overarching principles, with the first principle being
the protection of participant rights, safety, and well-being above scientific or societal
interests. This principle is foundational to all GCP guidelines and remains unchanged from
E6(R2), though R3 makes it more explicit within a principles-based framework .
SOCRA Exam Note: E6(R3) restructures GCP around eight principles rather than procedural
sections. Know that participant protection is the paramount principle.
Q2: Under 21 CFR 50.25, which element is NOT required in informed consent documentation?
A. Description of any reasonably foreseeable risks or discomforts
B. Description of any benefits to the subject or others
C. Statement that the study drug is FDA-approved for the investigational indication
[CORRECT]
D. Disclosure of appropriate alternative procedures or treatments
,Correct Answer: C
Rationale: 21 CFR 50.25 specifically prohibits suggesting that investigational products are
"safe or effective for the purposes for which they are being investigated." Investigational
products are by definition not approved for the indication being studied. Options A, B, and D
are all required basic elements per 50.25(a)(1), (2), and (3).
Regulatory Alert: Stating that an investigational drug is FDA-approved for the investigational
use constitutes misbranding and violates informed consent requirements.
Q3: A clinical trial is being conducted under an IND in the United States. According to FDA
regulations, how long does the FDA have to review the initial IND submission before the
sponsor may proceed with the study?
A. 15 calendar days
B. 30 calendar days [CORRECT]
C. 45 calendar days
D. 60 calendar days
Correct Answer: B
Rationale: Per 21 CFR 312.40, an IND automatically becomes effective 30 days after receipt
by the FDA unless the agency imposes a clinical hold or provides earlier notification that
studies may begin. This applies to both commercial and non-commercial INDs .
SOCRA Exam Note: The 30-day safety review period is distinct from IRB approval timelines,
which vary by institution.
Q4: According to ICH E6(R3), which of the following represents a NEW principle not explicitly
stated in E6(R2)?
A. Protection of participant rights, safety, and well-being
B. Informed consent must be freely given before participation
C. Reliability of results [CORRECT]
D. Independent ethics committee review is required
Correct Answer: C
Rationale: While E6(R2) implied the importance of reliable data, E6(R3) explicitly adds
"Reliability of results" as a standalone principle, emphasizing that reported trial results must
be credible and that processes must ensure data integrity for valid decision-making.
Principles A, B, and D were present in E6(R2) .
,Q5: An IRB reviewing a pediatric protocol must ensure compliance with which additional
regulatory subpart beyond 21 CFR 50 and 56?
A. 21 CFR 11 (Electronic Records)
B. 21 CFR 54 (Financial Disclosure)
C. 21 CFR 50 Subpart D (Additional Safeguards for Children) [CORRECT]
D. 21 CFR 312 (IND Regulations)
Correct Answer: C
Rationale: 21 CFR 50 Subpart D provides specific protections for children involved in
research, including requirements for parental permission, child assent, and risk
categorization (minimal risk, minor increase over minimal risk, etc.). This is in addition to
standard IRB requirements under 21 CFR 56 and informed consent under 21 CFR 50.
Q6: Under the HIPAA Privacy Rule (45 CFR 164.512(i)), which authorization requirement
applies specifically to research uses of protected health information?
A. Authorization must specify the purpose of the research
B. Authorization must have an expiration date or event [CORRECT]
C. Authorization must be obtained from the treating physician
D. Authorization must be notarized
Correct Answer: B
Rationale: 45 CFR 164.508 requires that authorizations for research include an expiration date
or event, such as "end of the research study" or "none" for ongoing research. While specifying
the purpose (A) is required, the expiration requirement is particularly critical for research.
Options C and D are not HIPAA requirements.
SOCRA Exam Note: Research authorizations under HIPAA differ from
treatment/payment/healthcare operations authorizations and must contain specific
research-focused elements.
Q7: According to ICH E6(R3), which stakeholder bears ultimate responsibility for ensuring
data integrity when clinical trial functions are outsourced to CROs or technology vendors?
A. The CRO or vendor performing the function
B. The principal investigator at each site
C. The sponsor [CORRECT]
D. The regulatory authority
Correct Answer: C
, Rationale: E6(R3) explicitly states that sponsors retain ultimate accountability even when
delegating activities. The sponsor must ensure adequate oversight of outsourced functions
and establish data governance frameworks covering all vendors. This is a strengthened
requirement in R3 compared to R2 .
Q8: Which of the following constitutes a "vulnerable population" under 45 CFR 46 Subpart C
requiring additional protections?
A. College students participating in psychology studies
B. Pregnant women [CORRECT]
C. Patients with well-controlled hypertension
D. Healthcare professionals
Correct Answer: B
Rationale: 45 CFR 46 Subpart B specifically addresses pregnant women, human fetuses, and
neonates as vulnerable populations requiring additional protections. Prisoners are covered
under Subpart C, and children under Subpart D. While college students and healthcare
professionals may have coercion concerns, they are not classified as vulnerable populations
requiring subpart-level protections.
Q9: According to 21 CFR 56.107, what is the minimum number of members required on an
IRB?
A. Three members
B. Five members [CORRECT]
C. Seven members
D. Ten members
Correct Answer: B
Rationale: 21 CFR 56.107(a) requires that each IRB have at least five members with varying
backgrounds. Additionally, 56.107(b) requires at least one member whose primary concerns
are scientific, one non-scientific, and one not affiliated with the institution.
Q10: Under the Belmont Report, which ethical principle is violated when researchers enroll
subjects without ensuring they understand the risks?
A. Respect for persons [CORRECT]
B. Beneficence
C. Justice
D. Non-maleficence
Correct Answer: A
ACTUAL EXAM 2026/2027 | ICH GCP
E6(R3) & FDA Regulations |
Comprehensive Practice Test | Verified
Q&A | Pass Guaranteed - A+ Graded
DOMAIN 1: REGULATORY ENVIRONMENT AND
COMPLIANCE (45 Questions)
Q1: According to ICH GCP E6(R3), which principle explicitly states that the "rights, safety, and
well-being of participants prevail over the interests of science and society"?
A. Principle of Scientific Integrity
B. Principle of Risk-Based Quality Management
C. Principle of Participant Protection [CORRECT]
D. Principle of Data Governance
Correct Answer: C
Rationale: ICH E6(R3) establishes eight overarching principles, with the first principle being
the protection of participant rights, safety, and well-being above scientific or societal
interests. This principle is foundational to all GCP guidelines and remains unchanged from
E6(R2), though R3 makes it more explicit within a principles-based framework .
SOCRA Exam Note: E6(R3) restructures GCP around eight principles rather than procedural
sections. Know that participant protection is the paramount principle.
Q2: Under 21 CFR 50.25, which element is NOT required in informed consent documentation?
A. Description of any reasonably foreseeable risks or discomforts
B. Description of any benefits to the subject or others
C. Statement that the study drug is FDA-approved for the investigational indication
[CORRECT]
D. Disclosure of appropriate alternative procedures or treatments
,Correct Answer: C
Rationale: 21 CFR 50.25 specifically prohibits suggesting that investigational products are
"safe or effective for the purposes for which they are being investigated." Investigational
products are by definition not approved for the indication being studied. Options A, B, and D
are all required basic elements per 50.25(a)(1), (2), and (3).
Regulatory Alert: Stating that an investigational drug is FDA-approved for the investigational
use constitutes misbranding and violates informed consent requirements.
Q3: A clinical trial is being conducted under an IND in the United States. According to FDA
regulations, how long does the FDA have to review the initial IND submission before the
sponsor may proceed with the study?
A. 15 calendar days
B. 30 calendar days [CORRECT]
C. 45 calendar days
D. 60 calendar days
Correct Answer: B
Rationale: Per 21 CFR 312.40, an IND automatically becomes effective 30 days after receipt
by the FDA unless the agency imposes a clinical hold or provides earlier notification that
studies may begin. This applies to both commercial and non-commercial INDs .
SOCRA Exam Note: The 30-day safety review period is distinct from IRB approval timelines,
which vary by institution.
Q4: According to ICH E6(R3), which of the following represents a NEW principle not explicitly
stated in E6(R2)?
A. Protection of participant rights, safety, and well-being
B. Informed consent must be freely given before participation
C. Reliability of results [CORRECT]
D. Independent ethics committee review is required
Correct Answer: C
Rationale: While E6(R2) implied the importance of reliable data, E6(R3) explicitly adds
"Reliability of results" as a standalone principle, emphasizing that reported trial results must
be credible and that processes must ensure data integrity for valid decision-making.
Principles A, B, and D were present in E6(R2) .
,Q5: An IRB reviewing a pediatric protocol must ensure compliance with which additional
regulatory subpart beyond 21 CFR 50 and 56?
A. 21 CFR 11 (Electronic Records)
B. 21 CFR 54 (Financial Disclosure)
C. 21 CFR 50 Subpart D (Additional Safeguards for Children) [CORRECT]
D. 21 CFR 312 (IND Regulations)
Correct Answer: C
Rationale: 21 CFR 50 Subpart D provides specific protections for children involved in
research, including requirements for parental permission, child assent, and risk
categorization (minimal risk, minor increase over minimal risk, etc.). This is in addition to
standard IRB requirements under 21 CFR 56 and informed consent under 21 CFR 50.
Q6: Under the HIPAA Privacy Rule (45 CFR 164.512(i)), which authorization requirement
applies specifically to research uses of protected health information?
A. Authorization must specify the purpose of the research
B. Authorization must have an expiration date or event [CORRECT]
C. Authorization must be obtained from the treating physician
D. Authorization must be notarized
Correct Answer: B
Rationale: 45 CFR 164.508 requires that authorizations for research include an expiration date
or event, such as "end of the research study" or "none" for ongoing research. While specifying
the purpose (A) is required, the expiration requirement is particularly critical for research.
Options C and D are not HIPAA requirements.
SOCRA Exam Note: Research authorizations under HIPAA differ from
treatment/payment/healthcare operations authorizations and must contain specific
research-focused elements.
Q7: According to ICH E6(R3), which stakeholder bears ultimate responsibility for ensuring
data integrity when clinical trial functions are outsourced to CROs or technology vendors?
A. The CRO or vendor performing the function
B. The principal investigator at each site
C. The sponsor [CORRECT]
D. The regulatory authority
Correct Answer: C
, Rationale: E6(R3) explicitly states that sponsors retain ultimate accountability even when
delegating activities. The sponsor must ensure adequate oversight of outsourced functions
and establish data governance frameworks covering all vendors. This is a strengthened
requirement in R3 compared to R2 .
Q8: Which of the following constitutes a "vulnerable population" under 45 CFR 46 Subpart C
requiring additional protections?
A. College students participating in psychology studies
B. Pregnant women [CORRECT]
C. Patients with well-controlled hypertension
D. Healthcare professionals
Correct Answer: B
Rationale: 45 CFR 46 Subpart B specifically addresses pregnant women, human fetuses, and
neonates as vulnerable populations requiring additional protections. Prisoners are covered
under Subpart C, and children under Subpart D. While college students and healthcare
professionals may have coercion concerns, they are not classified as vulnerable populations
requiring subpart-level protections.
Q9: According to 21 CFR 56.107, what is the minimum number of members required on an
IRB?
A. Three members
B. Five members [CORRECT]
C. Seven members
D. Ten members
Correct Answer: B
Rationale: 21 CFR 56.107(a) requires that each IRB have at least five members with varying
backgrounds. Additionally, 56.107(b) requires at least one member whose primary concerns
are scientific, one non-scientific, and one not affiliated with the institution.
Q10: Under the Belmont Report, which ethical principle is violated when researchers enroll
subjects without ensuring they understand the risks?
A. Respect for persons [CORRECT]
B. Beneficence
C. Justice
D. Non-maleficence
Correct Answer: A
